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from pragmatic trials, and another 4 studies (23.5%) from observational studies. 
The odds ratio for effectiveness versus efficacy being cost-effective was 8.75 (95% 
confidence interval; 0.74 to 103.82). ConClusions: Most CEA studies in asthma 
used efficacy data to inform CEA. Studies using effectiveness data trend toward 
being more likely to disseminate cost-effective findings than those using efficacy 
data. Health policy decision makers should pay attention to the type of “E” evidence 
used in CEAs for accurate interpretation and application.
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objeCtives: A cost-effectiveness model can be populated using mortality rates 
from a period’s life-table or using extrapolations of mortality based on historical 
life-tables. Current decision models use the first method. This simulation study aims 
at identifying the impact of mortality methods used on cost effectiveness analy-
ses. Methods: A simulation study was designed based on a two-state Markov model 
(alive-death) that compared a hypothetical intervention against no intervention. The 
model was populated with age-specific, all-cause mortality probabilities from the 
estimation methods presented above. The mortality extrapolations were estimated 
using a smoothed Lee-Carter method. The model outcomes were incremental costs, 
life-years gained (LYG) and incremental net benefit (INB). The proportional difference 
(PD) of the model outcomes between the two mortality estimation methods was the 
outcome of each simulation. The following parameters were simultaneously varied: 
discounting rate (0- 0.05), intervention effect (relative risk of mortality: 0.9-0.99), age 
at intervention (birth- 80 years old), duration of intervention effect (1 year/10 years/ 
lifelong), duration of intervention administration. Simulations were conducted using 
Canadian life-tables. The impact of each parameter on the simulation outcomes was 
estimated using descriptive and graphical methods. Results: The cohorts’ age and 
the discount level had an important effect on the PD in all outcomes (LYG, incremental 
cost and NHB) The duration of intervention effect and administration were more 
influential on the effect of method on the PD of incremental costs and INB. Large 
variation was observed among the scenarios within parameter values, for the PD of 
all outcomes. ConClusions: When using mortality projection methods, substantial 
differences were observed in CEA model outcomes. Given that the magnitude and the 
direction of the impact of mortality estimation methods on the model outcomes is 
multifactorial, decisions on the mortality estimation method used in economic evalu-
ations should be considered after conducting sensitivity analyses using both methods.
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CanCEr OutCOMEs rEsEarCH stuDiEs
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objeCtives: The objective of this study is to examine the prevalence of chronic 
conditions and their impact on the economic burden among cancer survivors in the 
United States. Methods: Using the 2008-2012 Medical Expenditure Panel Survey 
(MEPS) we identified 8,617 cancer survivors and 111,695 individuals without a his-
tory of cancer. Adjusted predictive margins from multivariable regression were used 
to examine the prevalence of chronic conditions. Direct medical costs were meas-
ured using annual health care expenditures and adjusted means were estimated 
using a two-part model. Indirect morbidity costs were calculated from the lost pro-
ductivity due to employment disability, missed work days, and lost household pro-
ductivity and adjusted means were estimated using multivariable logistic regression 
and negative binomial regression modelling. Separate models were used to evaluate 
the impact of each chronic condition and the impact of MCCs. Results: Cancer 
survivors were more likely to have MCCs, with 12.4% reporting ≥ 4 chronic conditions 
compared to 9.3% of individuals without a history of cancer. Medical expenditures 
for cancer survivors with other chronic conditions, particularly those with MCCs 
were higher than among cancer survivors without any of the chronic conditions 
studied. The largest increase in medical expenditures was associated with heart 
disease ($4,287) and stroke ($4,210). Having ≥ 4 chronic conditions was associated 
with increased expenditures of $9,082 per cancer survivor. Lost productivity was 
greater among cancer survivors with other chronic conditions. The largest increase 
in lost productivity was associated with stroke ($4,144) and arthritis ($3,426). Having 
≥ 4 chronic conditions was associated with increased lost productivity of $9,245 
per cancer survivor. ConClusions: Chronic conditions, especially the presence 
of MCCs, are associated with higher medical expenditures and lost productivity 
among cancer survivors. Efforts to reduce the health and economic burden caused 
by chronic conditions among cancer survivors are important given their substantial 
impact on medical expenditures and lost productivity.
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rEsEarCH On MODEling MEtHODs stuDiEs
MO1
rEDuCing anD Quantifying OvEr-fitting in rEgrEssiOn MODEls
Rigg J., Hankins M.
IMS Health, London, UK
objeCtives: Regression models are the multivariable analytical method of choice 
for epidemiologists and statisticians. It is widely recognized that these models may 
suffer from over-fitting, where the sample estimates fail to generalize to other sam-
ples. Systematic approaches to minimize over-fitting are seldom adopted and there 
is a reluctance to hold data back for independent assessment of model performance. 
This study assesses penalized regressions for reducing over-fitting, cross-validation 
on training data for estimating over-fitting, and the extent to which over-fitting 
produces misleading conclusions. Methods: Data were extracted from the IMS 
PharMetrics Plus US medical claims database for patients with Multiple Sclerosis 
receiving one of two treatments. Cohorts were matched using propensity scoring, 
producing 3,348 matched pairs. The probability of relapse and persistence were 
estimated using standard, stepwise and (LASSO) penalized logistic regressions. 
Over-fitting was measured as the difference between the Area Under Curve (AUC) 
for training and test data and additionally estimated using cross-validation on 
training data alone. Results: Penalized logistic regressions greatly reduced over-
fitting compared to standard and stepwise alternatives, irrespective of the choice 
of response variable and degrees of freedom: for example, modelling relapse with 
50% of the data used for training and 50% used for testing showed overfitting of 
9.9% with standard, 8.0% with stepwise and 3.9% with penalized logistic regression. 
Cross-validation provided reasonable approximations for over-fitting; estimated 
over-fitting for the above standard logistic model was 10.4%. Over-fitting inflated 
the estimated treatment effect by 25% (OR= 2.03 vs. 1.64; standard logistic model 
vs. penalized model). ConClusions: Penalized logistic regression models had 
substantially lower over-fitting. Moreover, good estimates of over-fitting can be 
derived without withholding data. Both penalized regressions and cross-validation 
are straightforward to implement in most statistical packages and greater adoption 
of these methods is encouraged to ensure more reliable estimates of risk factors.
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apprOaCHEs fOr antiplatElEt usE in tHE sECOnDary prEvEntiOn Of 
tHrOMBOtiC EvEnts aftEr MyOCarDial infarCtiOn (Mi)
Ozer-Stillman I.1, Whalen J.D.2, Bash L.D.3, Du M.1, Oguz M.1, Singhal P.K.4, Davies G.M.4
1Evidera, Lexington, MA, USA, 2Evidera, London, UK, 3Merck and Co., Inc., Rahway, NJ, USA, 
4Merck and Co., Inc., North Wales, PA, USA
objeCtives: A state transition model (STM) and a discrete event simulation (DES) 
were developed to evaluate the health outcomes associated with antiplatelet treat-
ments for secondary prevention of thrombotic events for patients with a recent 
myocardial infarction (MI) in the UK. Methods: The STM and DES were devel-
oped with similar assumptions about which events altered risk. In both models, 
results were compared between the vorapaxar plus standard care (VOR) and the 
standard care (SC) arms. Individual patient characteristics at baseline from the quali-
fying MI cohort of TRA 2°P-TIMI 50 trial were used to define patient profiles in both 
models; risk equations developed from the trial were used to estimate MI, stroke, 
and cardiovascular-related death risk. Bleeding event risks, case fatality rates, non-
cardiovascular mortality, and utilities were taken from published studies or UK sta-
tistics. Results: In the base case, for the VOR and SC arms, the DES predicted 13.93 
and 13.70 quality-adjusted life years (QALYs), respectively, versus 12.27 and 11.81 in 
the STM. The DES predicted 0.268 MIs, 0.140 strokes, and 0.318 CV-deaths per patient 
in the VOR arm, and 0.279 MIs, 0.145 strokes, and 0.325 CV-deaths per patient in the 
SC arm. The STM predicted 0.226 MIs, 0.132 strokes, and 0.417 CV-deaths per patient 
in the VOR arm, and 0.234 MIs, 0.136 strokes, and 0.435 CV-deaths per patient in the 
SC arm. ConClusions: Although these two models have very different structures, 
both estimated similar outcomes. The DES predicted more MI and stroke events than 
the STM, as patients can have multiple events in a short time frame rather than one 
event per model cycle. While both approaches are valid, the DES technique offers 
greater flexibility through its ability to consider many risk-changing events without 
“exploding” health states and to track changes in risk factors more efficiently.
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DOEs tHE usE Of EffiCaCy Or EffECtivEnEss EviDEnCE in COst-
EffECtivEnEss analysEs MattEr?
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objeCtives: Clinical efficacy or effectiveness (the “E”) is one driver of cost-effec-
tiveness analysis (CEAs). The type of “E” used in each CEA depend on the objectives 
and corresponding data sources. Applying different types of the “E” might affect 
CEA conclusions, but little is known. We aim to test the association of type of “E” 
and cost-effectiveness conclusions using asthma CEAs as an example. Methods: 
A systematic review was performed with 5 electronic databases from 2009 to 2014. 
All CEA studies evaluating asthma medication(s) and reporting incremental cost 
per quality-adjusted life year (QALY) were included. The “E” which was derived from 
an explanatory randomized controlled trial(s) (RCT) or meta-analysis of RCTs was 
defined as efficacy, while the “E” from a pragmatic RCT(s), an observational study, or 
registry was classified as effectiveness. Three times the World Health Organization 
Gross Domestic Product was used to determine a cost-effectiveness willingness-to-
pay threshold per QALY gained. Logistic regression was used to associate type of “E” 
and cost-effectiveness conclusions. Results: A total of 17 CEAs were included. Nine 
studies (52.9%) used efficacy evidence, while 8 studies (47.1%) used effectiveness 
evidence. Ten studies (58.8%) were modeling-based studies, while 7 studies (41.2%) 
were CEA-alongside-clinical trials. The “E” of 5 studies (29.4%) were derived from 
explanatory RCTs, 4 studies (23.5%) from meta-analysis of RCTs, 4 studies (23.5%) 
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underestimation of resource use costs. ConClusions: The study findings indicate 
that manufacturers should consider providing data supporting OS benefit versus 
relevant comparators. Also, a robust economic model including sensitivity analysis 
to adjust for uncertainties, and incorporating appropriate cost and utility values 
could be beneficial to gain access in CEA markets.
COnCEptual papErs
Cp1
MEtHODs tO assEss tHE assOCiatiOn Of patiEnt-rEpOrtED OutCOMEs 
anD CliniCal EnDpOints
Odom D., McLeod L., Sherif B., Nelson L.
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objeCtives: Patient-reported outcomes (PROs) are designed to measure the unique 
patient perspective on an aspect(s) of a disease or the impact of treatment. After the 
development and validation of a PRO measure, often the next step is to understand 
how the PRO scores and changes are related to the clinical endpoints in order to 
better inform and interpret the newly developed PRO for clinician use or to provide 
greater insights into disease burden or treatment efficacy. Our objective is to review 
commonly used statistical Methods when assessing the association of PRO and 
clinical endpoints and to introduce alternate statistical applications. Methods: 
A review of the literature revealed several statistical Methods used to define and 
quantify the association between PROs and clinical endpoints including correlation 
analysis, responder/categorical analysis, linear and logistic regression and receiver-
operating curves. However, these methodologies typically examine the relationship 
at a single time-point, ignoring the longitudinal nature of the study design. Our 
research will use simulated longitudinal data to examine the association between 
PROs and clinical endpoints across multiple time-points and introduce alternate 
applications using mixed-models for repeated measures. We will provide a series of 
examples based on the simulated data to show how each method uniquely demon-
strates the relationship between these endpoints. ConClusion: To help stakehold-
ers understand the relevance of PROs, it is often an important step to assess the 
association of a PRO to existing clinical endpoints. Our research introduces alternate 
approaches to examine this association across multiple time-points which account 
for the longitudinal design found in most trials.
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bACkgRound: In many cases, medicines for ultra-rare disorders (URDs) have high 
acquisition costs and are associated with incremental cost per quality-adjusted 
life year (QALY) gained exceeding widely used benchmarks for cost effective-
ness. objeCtives: To address the underlying reasons why interventions for URDs 
often fail to meet conventional benchmarks for cost effectiveness and deliberate 
implications for formal Health Technology Assessments (HTAs) including economic 
evaluation. Methods: An international group of experts in health economics, med-
ical ethics, evidence-based medicine (EBM), and HTA met in conjunction with the 
Annual European ISPOR Congresses in November 2012, 2013, and 2014. Results: 
In contrast to the principles of EBM, the logic of cost effectiveness (including bench-
marks for incremental cost per QALY gained, as applied by some HTA agencies as a 
measure of “value for money”) does not adequately capture well-established social 
norms and preferences regarding health care resource allocation. Such preferences 
include, but are not limited to, a priority for care for the worst off (related to initial 
health state), for those with more urgent conditions (the so called “rule of rescue”), 
and a relatively lower priority based upon capacity to benefit, as well as a dislike 
against “all or nothing” resource allocation decisions that might deprive certain 
groups of patients from any chance to access effective care. ConClusions: The 
group concluded that there exists a strong need for an improved or new paradigm to 
assess value for money. Candidates include direct social value measurement using 
the relative social willingness-to-pay or person trade-off instruments, combined 
with a greater role for budget impact analysis. As a pragmatic interim alternative, 
multi-criteria decision analysis may prove useful. Further systematic research into 
social preferences, including their valid measurement, should be prioritized relative 
to the continued application of a descriptively flawed framework based on bench-
marks for maximum incremental cost per QALY gained.
Cp3
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objeCtives: To describe a framework for the integration of encompassing models of 
value into health technology assessment (HTA) decision processes, and to use this to 
work through the implications of implementing broader models of value, using an 
‘end-of-life premium’ as an exemplar proposition. Methods: Building on a scoping 
review of the literature on the role of values in HTA and the use of cost-effectiveness 
objeCtives: Patients with metastatic non-small cell lung cancer (NSCLC) whose 
tumors harbor exon 19 deletions or exon 21 (L858R) substitution mutations in the 
epidermal growth factor receptor (EGFR) gene are eligible for first line treatment 
with erlotinib or afatinib, tyrosine kinase inhibitors (TKIs) approved for use in the 
U.S. The relative clinical and economic impacts between these two agents remain 
unclear. Methods: A Markov model was developed in which patients could transi-
tion through three health states: Pre progression, progression, and death. Transition 
probabilities were derived from key clinical trials, peer-reviewed literature, and U.S. 
life tables. We assumed a progression free survival (PFS) hazard ratio (HR) of 1 in 
the base case, and a scenario analysis was performed using data from an indirect 
treatment comparison in which the PFS HR for erlotinib vs. afatinib was 0.44. Costs 
included those related to drug utilization, drug administration, and adverse events. 
We calculated the discounted (3%) incremental life expectancy, quality-adjusted 
life expectancy, and costs from a U.S. payer perspective. Probabilistic sensitivity 
analysis (PSA) was conducted to assess parameter uncertainty. Results: Initiating 
treatment with erlotinib rather than afatinib resulted in comparable QALYs and 
modest decreased costs (-$895) in the base case. PSA indicated that at a threshold 
of $100,000/QALY, there was approximately a 60% probability that erlotinib is cost-
effective. In the scenario analysis (PFS HR: 0.44) we found that erlotinib treatment 
resulted in $35K greater costs and 0.274 additional QALYs gained, resulting in an 
ICER of $128K/QALY. ConClusions: Our analysis indicates that first-line treatment 
with erlotinib vs. afatinib may lead to similar quality adjusted life years gained but 
slightly lower costs. Depending on assumptions about the comparative effective-
ness, erlotinib may be in the range of being cost effective compared to afatinib, even 
with significantly longer PFS and treatment duration.
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objeCtives: To analyze all available clinical trial evidence to determine whether 
dose-intensive therapy Results in longer overall survival (OS) or progression-free 
survival (PFS) in DHL patients who have poorer prognoses than standard-risk diffuse 
large B-cell lymphoma patients. Methods: Eleven observational studies evaluat-
ing first-line treatments in 401 adult DHL patients were included (no randomized 
trials were available). Individual patient data (IPD) were obtained from authors of 2 
studies; IPD was extracted from digitized Kaplan-Meier survival curves of 3 studies. 
Median survival (n= 4) and percent survival at month 24 (n= 2) were available from 
the remaining publications. All data types were synthesized within a random-effects 
Weibull proportional hazards model using a Bayesian analysis framework to esti-
mate OS and PFS of each treatment. IPD points were given Weibull distributions, cen-
sored as necessary. The number of survivors at median or month 24 was estimated 
from the total number of patients and assumed binomially distributed. The binomial 
probabilities were then used to inform the Weibull survival parameters. Treatments 
of interest were R-CHOP (standard dose), R-EPOCH (intermediate dose), and R-Hyper-
CVAD or R CODOX-M/R-IVAC (dose-intense [DI]). Results: Appropriateness of the 
Weibull and proportional hazards assumptions was verified by graphical tests using 
the available IPD. Estimated hazard ratios (HRs) of OS (n= 374) relative to R-CHOP 
were 0.77 (95% credible interval: 0.51-1.13) for R-EPOCH and 0.89 (0.62-1.27) for DI, 
indicating no significant differences for either higher-dose treatment. R-EPOCH, 
but not DI, was associated with a marginally significant increase in PFS (n= 357) 
with HRs of 0.66 (0.44-0.96) and 0.74 (0.51-1.05), respectively. ConClusions: This 
novel methodology combines several data types, allowing synthesis of data from 
a larger number of studies than could have been possible with standard analysis 
techniques. The totality of the available published data suggested R-EPOCH chemo-
therapy extended PFS, but not OS in DHL patients.
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rEiMBursEMEnt DECisiOn lanDsCapE fOr MEtastatiC BrEast CanCEr 
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unfavOraBlE rECOMMEnDatiOns aCrOss lEaDing Hta agEnCiEs
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objeCtives: To compare the reimbursement recommendations and ration-
ale for decisions for metastatic breast cancer therapies across seven HTA agen-
cies. Methods: We assessed HTA reports published by AHRQ, HAS, IQWiG, NICE, 
PBAC, pCODR and SMC for metastatic breast cancer therapies. Decisions were cat-
egorized as positive, negative or deferred, and recommendation summaries were 
analyzed to identify clinical and economic factors affecting decisions. Results: 
Thirty-nine HTA reports were identified, of which 46% had a positive recommenda-
tion. No relevant HTA reports were published by AHRQ. Highest positive decisions 
were provided by pCODR (80%), all being conditional on improving cost-effectiveness 
to an acceptable level. Major factors driving positive decisions were overall survival 
(OS) benefit for IQWiG and pCODR; acceptable efficacy and safety for HAS; and 
cost-effectiveness versus relevant comparator(s) for NICE, PBAC and SMC. Highest 
percentage of negative decisions was provided by NICE (75%). HAS cited lack of 
survival benefit (OS or progression-free survival) or quality-of-life improvement, 
or unacceptable safety profile for negative decisions; whereas, pCODR and IQWiG 
mainly considered lack of OS benefit and inappropriate comparators. Negative 
decisions by NICE, PBAC and SMC were mainly due to economic modelling issues 
that resulted in high ICERs. NICE also considered lack of quality-of-life benefit and 
unacceptable safety profile for negative decisions. Major economic modelling issues 
across HTA agencies included inappropriate extrapolation of immature OS data, 
carry-over of benefit into post-treatment states, improper cross-over adjustment, 
non-inclusion of adverse event-related disutilities and costs, underestimation of 
post-progression utility and costs, overestimation of comparator drug costs, and 
